Completed PHASE3 INTERVENTIONAL NCT00168181

Trial Comparing Oral Pilocarpine (Salagen) Versus Submandibular Salivary Gland Transfer Protocol, For the Prevention of Radiation (XRT) Induced Xerostomia in Head and Neck Cancer Patients

A Phase III Randomized Trial Comparing Oral Pilocarpine (Salagen) Versus Submandibular Salivary Gland Transfer Protocol, For the Prevention of Radiation (XRT) Induced Xerostomia in Head and Neck Cancer Patients

Sponsor: Alberta Health services

Conditions Cancer Head and Neck Cancer

Interventions Salagen Submandibular gland Transfer

Updated 6 times since 2017 Last updated: Apr 15, 2011 Started: Apr 30, 2002 Completion: Apr 30, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Cancer and Head and Neck Cancer, this trial is completed. The trial is conducted by Alberta Health services and has accumulated 6 data snapshots since 2002. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Nov 2022 — Jul 2024 [monthly]

Completed PHASE3
Jan 2021 — Nov 2022 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Apr 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Alberta Health services
CancerCare Manitoba
Jewish General Hospital
Newfoundland Cancer Treatment & Research Foundation
Notre-dame Hospital
Ottawa Hospital Research Institute

Data source: AHS Cancer Control Alberta

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Edmonton, Canada